News | Congenital Heart | March 24, 2021

Critical Need for Pediatric Electrophysiology Devices is Focus of Medical Device Competition 

National Capital Consortium for Pediatric Device Innovation will provide $150,000 awards for technology to address unmet EP needs

Neonates and young pediatric patients with congenital heart disease have few options for implantable electrophysiology (EP) devices like pacemakers or ICDs.

March 24, 2021 — Congenital heart disease (CHD) affects six out of 1,000 babies born in the U.S. each year and is often complicated by arrhythmias. While the last decade brought great advances in technologies that improve the care of adult arrhythmias, pediatric patients have been left behind, with only five devices approved for use in children in the same period. As a result, pediatric specialists are often using off-label or improvised electrophysiology (EP) devices to treat pediatric arrhythmias, including in the smallest newborns.

Recognizing this unmet need, the National Capital Consortium for Pediatric Device Innovation (NCC-PDI), in collaboration with MedTech Innovator, is accepting applications through April 12, 2021, for its annual "Make Your Medical Device Pitch for Kids!" competition. This year's competition focuses on innovations in pediatric devices that treat CHD, with an emphasis on electrophysiology devices such as pacemaker systems, ablation catheters, wearable monitoring devices and related technologies that address arrhythmias in children.

"NCC-PDI was created, with the support of the Food and Drug Administration (FDA), to seek out and address significant unmet needs in pediatric medical devices," saaid Kolaleh Eskandanian, Ph.D., M.B.A., P.M.P., vice president and chief innovation officer at Children's National Hospital and principal investigator of NCC-PDI. "We have learned from the experts that pediatric-specific technologies for treating arrhythmias would be a game changer in the care of their patients, so we are focusing our competition and grant awards on this opportunity."

Using a virtual format, semi-finalists chosen from all submissions will make their first pitch on May 12, 2021. Up to 10 finalists selected from this event earn participation in a special pediatric-focused track of the MedTech Innovator accelerator program, the largest medtech accelerator in the world, beginning in June 2021. These innovators then participate in the pediatric competition finals in September 2021 where judges will award up to $150,000 in FDA-sponsored grants to the devices selected as most impactful and commercially viable. 

"Because pediatric medical devices face unique challenges in achieving commercialization, MedTech Innovator's accelerator program provides specialized mentoring and guidance from experienced industry leaders," said Paul Grand, CEO of MedTech Innovator. "Our program is designed to provide immediate and long-term benefits to help innovators more rapidly achieve success on their journey to improving health care for children."

How significant is the need for pediatric devices to address arrhythmias? In a recent survey of members conducted by the Pediatric and Congenital Electrophysiology Society (PACES), the vast majority (96%) said they believe there is a deficiency in devices available to serve the needs of pediatric patients. Conducted with the U.S. FDA, the survey also asked respondents to identify the biggest unmet need, which physicians identified as cardiovascular implantable electronic devices that are smaller, have better battery life and have pediatric-specific algorithms. Specifically, a leadless pacemaker designed for pediatric care was consistently on the most-wanted list.

"It's evident that technologies for pediatric patients with CHD are not adequate and the experts are telling us what they need," said William E. Bentley, Ph.D., Robert E. Fischell distinguished professor and director of the Robert E. Fischell Institute for Biomedical Devices at the University of Maryland. "I look forward to seeing the critical innovations that NCC-PDI will help to advance through this competition."

NCC-PDI is one of five members in the FDA's Pediatric Device Consortia Grant Program created to support the development and commercialization of medical devices for children, which lags significantly behind the advancement of adult medical devices. NCC-PDI is led by the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Hospital and the A. James Clark School of Engineering at the University of Maryland with support from partners MedTech Innovator, BioHealth Innovation and design firm Archimedic.

Eskandanian said that enhancing access to resources for pediatric innovators is also one of the aims of the Children's National Research and Innovation Campus, a first-of-its-kind focused on pediatric health care innovation, with the first phase currently open on the former Walter Reed Army Medical Center campus in Washington, D.C. With its proximity to federal research institutions and agencies, universities, academic research centers, as well as on-site incubator Johnson & Johnson Innovation – JLABS, the campus provides a rich ecosystem of public and private partners which, like the NCC-PDI network, will help bolster pediatric innovation and commercialization.

For more information and to apply for the upcoming NCC-PDI pitch competition: https://innovate4kids.smapply.io/prog/2021/

 

Related Content

Images from the ASE presentation. Left, UEA echo showing focal narrowing of the SCPC anastomosis and the same view on invasive angiography. Right, UAE echo showing complete occlusion of pulmonary artery and angiography showing the same view.

Images from the ASE presentation. Left, UEA echo showing focal narrowing of the SCPC anastomosis and the same view on invasive angiography. Right, UAE echo showing complete occlusion of pulmonary artery and angiography showing the same view.

News | Congenital Heart | June 29, 2021
June 29, 2021 – Echocardiography with ultrasound enhancing agents (UEAs) has proven to be a valuable imaging procedur
The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent. It is used for repair of sinus venosus atrial septal defects (SVASD). #SVASD #SCAI2021 #congenitalheart #

The NuMED 10-zig Covered CP (CCP) balloon expandable covered stent.

News | Congenital Heart | May 01, 2021
May 1, 2021 - An analysis of a new international registry reveals benefits of using a longer covered stent for interv
News | Congenital Heart | February 16, 2021
February 16, 2021 – In recognition of World...
The Smidt Heart Institute at Cedars-Sinai is working with the Keck Medicine of USC heart surgery team to expand care for children and adults with congenital heart disease. An echocardiographer helps with cardiac ultrasound imaging in a hybrid OR during a congenital case using a Siemens SC2000 imaging system. Photo by Cedars-Sinai.

The Smidt Heart Institute at Cedars-Sinai is working with the Keck Medicine of USC heart surgery team to expand care for children and adults with congenital heart disease. An echocardiographer helps with cardiac ultrasound imaging in a hybrid OR during a congenital case using a Siemens SC2000 imaging system. Photo by Cedars-Sinai.

News | Congenital Heart | August 10, 2020
August 10, 2020 - The...
Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects. #SCAI #SCAI2020

Left, the Melody pulmonary valve was the first transcatheter valve to be approved by the FDA in the United States a decade ago. Right, the Harmony transcatheter valve is in trials and is designed to treat patients with RVOT anomalies who develop severe PR typically when a pervious repair fails. Both valves are used to treat congenital heart defects.

News | Congenital Heart | May 21, 2020
May 21, 2020 — Two late-breaking clinical trials on trans catheter valves to treat congenital heart disease were pres
SCAI Issues Position Statement on Adult Congenital Cardiac Interventional Training, Competencies and Organizational Recommendations. A congenital atrial septal defect closed using a transcatheter occluder, visualized on 3-D TEE ultrasound.

A congenital atrial septal defect closed using a transcatheter occluder, visualized on 3-D TEE ultrasound.

News | Congenital Heart | May 04, 2020
University of Arizona Leads Statewide Study of Congenital Heart Defects
News | Congenital Heart | October 24, 2019
Investigators at the University of Arizona Steele Children's Research Center are leading a statewide study as part of a...
Abbott Receives European CE Mark for Two Pediatric Heart Devices
News | Congenital Heart | September 20, 2019
Abbott announced approvals in Europe for two of its pediatric devices — the Masters HP 15mm rotatable mechanical heart...
High Blood Pressure, Cholesterol in Young Adults Associated With Later Heart Disease
News | Congenital Heart | July 16, 2019
Elevated blood pressure and cholesterol levels in young adulthood may lead to an increased risk of heart disease later...